Currently, there are 494.33M common shares owned by the public and among those 486.97M shares have been available to trade.
The company’s stock has a 5-day price change of -0.48% and -14.23% over the past three months. ELAN shares are trading -16.64% year to date (YTD), with the 12-month market performance down to -2.97% lower. It has a 12-month low price of $11.40 and touched a high of $18.80 over the same period. ELAN has an average intraday trading volume of 4.71 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.01%, -7.15%, and -15.38% respectively.
Institutional ownership of Elanco Animal Health Inc (NYSE: ELAN) shares accounts for 98.02% of the company’s 494.33M shares outstanding.
It has a market capitalization of $6.14B and a beta (3y monthly) value of 1.41. The stock’s trailing 12-month PE ratio is 30.40, while the earnings-per-share (ttm) stands at $0.41. The company has a PEG of 3.04 and a Quick Ratio of 1.31 with the debt-to-equity ratio at 0.67. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.92% over the week and 3.48% over the month.
Earnings per share for the fiscal year are expected to increase by 2.89%, and -0.47% over the next financial year.
Looking at the support for the ELAN, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on December 09, 2024, with the firm’s price target at $18. Leerink Partners coverage for the Elanco Animal Health Inc (ELAN) stock in a research note released on December 02, 2024 offered a Market Perform rating with a price target of $14. Morgan Stanley was of a view on September 19, 2024 that the stock is Equal-Weight, while Stifel gave the stock Buy rating on January 05, 2024, issuing a price target of $13- $20. Jefferies on their part issued Buy rating on December 19, 2023.
